Hudson Bay Capital Management LP Acquires 105,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Hudson Bay Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 87.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,000 shares of the company’s stock after acquiring an additional 105,000 shares during the period. Hudson Bay Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $4,545,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Howard Bailey Securities LLC raised its holdings in Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after acquiring an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. grew its stake in Teva Pharmaceutical Industries by 1.6% in the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after purchasing an additional 515 shares in the last quarter. CIBC Private Wealth Group LLC increased its position in shares of Teva Pharmaceutical Industries by 15.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after purchasing an additional 540 shares during the last quarter. Retirement Planning Co of New England Inc. raised its stake in shares of Teva Pharmaceutical Industries by 1.8% during the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after purchasing an additional 588 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Teva Pharmaceutical Industries by 0.5% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock worth $1,981,000 after purchasing an additional 615 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TEVA shares. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Jefferies Financial Group lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research note on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts remain constructive: a blended analyst target around $37.67 and multiple recent upgrades/target raises suggest upside vs. the current share price, supporting positive sentiment among buy-side and brokers. Brokerages Set Teva Price Target at $37.67
• Positive Sentiment: Teva published its Q1 2026 Aide Memoire on the investor site — this consolidates prior public disclosures and reduces surprise risk ahead of Q1 results, which can limit downside from unexpected disclosures. Teva Releases Q1 2026 Aide Memoire
• Neutral Sentiment: Teva set a firm date for Q1 2026 results: press release on April 29 at 7:00 a.m. ET followed by a conference call/webcast at 8:00 a.m. ET — gives investors a clear roadmap to reprice the stock on confirmed quarterly metrics and management commentary. Teva to Host Q1 2026 Conference Call
• Negative Sentiment: Insider selling: Mark Sabag sold 62,102 shares on March 17 at an average $30.14 (≈$1.87M), trimming his stake by ~21.6% — significant insider sales can hurt near-term sentiment even if they are for personal/liquidity reasons. Insider Sale Disclosure — Mark Sabag

Teva Pharmaceutical Industries Stock Down 2.5%

TEVA opened at $28.72 on Friday. The stock’s fifty day simple moving average is $32.66 and its 200 day simple moving average is $27.07. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35. The stock has a market cap of $33.02 billion, a PE ratio of 23.93, a price-to-earnings-growth ratio of 9.62 and a beta of 0.72. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the business posted $0.71 earnings per share. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. The trade was a 9.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president directly owned 85,755 shares in the company, valued at approximately $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 920,901 shares of company stock worth $30,056,789 in the last ninety days. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.